Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) pipeline Target constitutes close to 27 molecules. Out of which approximately 27 molecules are developed by Companies. The latest report GMDHC22029TDB - Tyrosine Protein Kinase SYK - Drugs In Development, 2022, outlays comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. It assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 10, 2, 10 and 1 respectively.

Report covers products from therapy areas Oncology, Immunology, Ophthalmology, Dermatology, Hematological Disorders, Respiratory, Central Nervous System, Infectious Disease and Musculoskeletal Disorders which include indications Diffuse Large B-Cell Lymphoma, Rheumatoid Arthritis, Allergic Conjunctivitis, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acquired (Autoimmune) Hemolytic Anemia, Asthma, Atopic Dermatitis (Atopic Eczema), Mantle Cell Lymphoma, B-Cell Chronic Lymphocytic Leukemia, Epithelial Ovarian Cancer, Follicular Lymphoma, Kidney Transplant Rejection, Marginal Zone B-cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Systemic Lupus Erythematosus, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lung Injury, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Respiratory Distress Syndrome, Allergies, Alopecia Areata, Alzheimer's Disease, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Arthritis, B-Cell Non-Hodgkin Lymphoma, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Obstructive Pulmonary Disease (COPD), Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Pneumonia, Cutaneous T-Cell Lymphoma, Fallopian Tube Cancer, Gastric Cancer, Hand Dermatitis, Hidradenitis Suppurativa, Idiopathic Pulmonary Fibrosis, Keratoconjunctivitis Sicca (Dry Eye), Ocular Inflammation, Peritoneal Cancer, Psoriasis, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Subacute Cutaneous Lupus Erythematosus (SCLE), Unspecified B-Cell Lymphomas, Unspecified Ophthalmological Disorders and Vitiligo.

Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
• The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned
Companies Mentioned

AB Science SA
Alexion Pharmaceuticals Inc
Aptose Biosciences Inc
Archer Pharmaceuticals Inc
Asana BioSciences LLC
Beijing Hanmi Pharmaceutical Co Ltd
Calithera Biosciences Inc
Clevexel Pharma SA
CSPC Pharmaceutical Group Ltd
Genosco Inc
GlaxoSmithKline Plc
Hutchison MediPharma Ltd
IACTA Pharmaceuticals Inc
Japan Tobacco Inc
Kronos Bio Inc
Levolta Pharmaceuticals Inc
Nano Biotherapeutics Inc
Origenis GmbH
Pulmatrix Inc
Rigel Pharmaceuticals Inc
Taiho Pharmaceutical Co Ltd